Krystal Biotech (KRYS) Cost of Revenue (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Cost of Revenue data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 25.76% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (up 7.38% YoY), and the FY2025 full-year result was $23.0 million, up 14.89% from the prior year.
• Cost of Revenue fell to $6.3 million in Q1 2026, from $6.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $7.2 million in Q2 2025 to a low of $223000.0 in Q3 2023.
• A 4-year average of $4.8 million and a median of $5.0 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 2897.31% in 2024 and tumbled 36.22% in 2025, its largest moves.
• Tracing KRYS's Cost of Revenue over 4 years: stood at $2.9 million in 2023, then surged by 72.38% to $4.9 million in 2024, then surged by 33.2% to $6.6 million in 2025, then fell by 4.08% to $6.3 million in 2026.
• Business Quant data shows KRYS's Cost of Revenue at $6.3 million in Q1 2026, $6.6 million in Q4 2025, and $4.3 million in Q3 2025.